MedTrace Logo

A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male Subjects

NCT04485884 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-11-09

No results posted yet for this study

Summary

The main purpose of this study is to evaluate pharmacokinetics/pharmacodynamics and safety/tolerability of IN-C005 after oral administration in healthy Korean and Caucasian male subjects.

Conditions

  • Healthy

Interventions

DRUG

IN-C005 dose A

One time dose of IN-C005 dose A taken orally.

DRUG

IN-C005 dose B

One time dose of IN-C005 dose B taken orally.

DRUG

IN-C005 dose C

One time dose of IN-C005 dose C taken orally.

DRUG

IN-C005 dose D

Oral administration of IN-C005 dose D once daily for 7 days.

DRUG

IN-C005 dose E

Oral administration of IN-C005 dose E once daily for 7 days.

DRUG

IN-C005 dose F

Oral administration of IN-C005 dose F once daily for 7 days.

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang, MD, PhD · Seoul National University Hospital, Clinical Trial Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-13
Primary Completion
2021-03-31
Completion
2021-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04485884 on ClinicalTrials.gov